BRKR vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak fundamental profile with a Piotroski F-Score of just 2/9, indicating poor financial health. Despite a reasonable Price/Book of 3.13 and a Forward P/E of 23.49 that is below sector average, the company is unprofitable with a negative profit margin (-0.61%) and ROE (-1.09%). Revenue is flat, earnings volatility is high, and insider selling of $2.76M over the past six months signals management skepticism. While the technical rebound from 6-month lows has lifted price performance (+20.3% over 6M), the long-term trend remains weak with a 3Y return of -28.5%, and analyst target of $54.07 appears optimistic given deteriorating fundamentals.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BRKR vs JNJ: Head-to-Head Comparison
This page compares Bruker Corporation (BRKR) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.